(RTTNews) - Jupiter Neurosciences, Inc. (JUNS), a clinical-stage pharmaceutical company, on Thursday announced a strategic partnership with Zina Biopharmaceuticals, LLC to support the execution of its upcoming Phase 2a clinical trial for Parkinson's disease.
Under the terms of the agreement, Zina will provide comprehensive services to assist with the clinical trial, including trial protocol design, regulatory strategy, pharmacokinetics, and site selection. The trial will focus on evaluating the safety and tolerability of JOTROL, Jupiter's patented resveratrol-based platform, in patients with Parkinson's disease.
JOTROL is an innovative micellar formulation that significantly enhances the bioavailability of resveratrol while minimizing gastrointestinal side effects.
Preclinical studies have shown that JOTROL has the potential to address neurodegeneration, making it a promising candidate for Parkinson's and other CNS disorders.
"We are thrilled to partner with Zina as we move JOTROL into Phase 2 clinical development," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "Zina's expertise in trial execution and regulatory strategy will be essential in accelerating our development timeline."
The partnership will help support Jupiter's goal to address the unmet medical need for Parkinson's treatments, with the global Parkinson's therapeutics market expected to exceed $14 billion by 2030.
Jupiter is also exploring further strategic partnerships to expand JOTROL's applications to other neuroinflammatory and metabolic disorders, such as Alzheimer's disease.
JUNS closed Wednesday's (Jan.29 2025) trading at $1.22 down by 7.58%. In premarket trading Thursday the stock is up 1.63% at $1.24.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
